Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.63 |
| ▸ | BCHE | P06276 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.56 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.54 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.54 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4411697 | 0.94 | PABPC1 (0.64) | PABPC1BCHEACHEABCB1CSNK2A2 | |
| SCHEMBL4399922 | 0.89 | ABCB1 (0.72) | BCHEACHEABCB1CSNK2A2CSNK2B | |
| SCHEMBL4403604 | 0.87 | BCHE (0.62) | BCHEACHEMAOB | |
| SCHEMBL6555693 | 0.84 | PABPC1 (0.76) | PABPC1ABCB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL4414243 | 0.83 | PABPC1 (0.60) | PABPC1BCHEACHEABCB1CSNK2A2 | |
| SCHEMBL4542681 | 0.78 | MEN1 (0.52) | PABPC1 | |
| SCHEMBL4399496 | 0.77 | PABPC1 (1.00) | PABPC1ABCB1CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL11101571 | 0.77 | BCHE (0.48) | BCHEACHEMAOB | |
| SCHEMBL4550526 | 0.77 | PABPC1 (0.51) | PABPC1 | |
| SCHEMBL4408552 | 0.76 | PABPC1 (0.57) | PABPC1ABCB1CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1807408-B1 | OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS | COUNCIL SCIENT IND RES (IN) | 2016-06-08 | — | — | EP | disclosed |
| US-7635779-B2 | Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2009-12-22 | — | — | US | disclosed |
| EP-1807408-A1 | OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS | Council of Scientific and Industrial Research (IN) | 2007-07-18 | — | — | EP | disclosed |
| US-20060178373-A1 | Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2006-08-10 | — | — | US | disclosed |
| WO-2006040621-A1 | OXY SUBSTITUTED FLAVONES AS ANTIHYPERGLYCEMIC AND ANTIDYSLIPIDEMIC AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178373-A1 | Oxy substituted flavones as antihyperglycemic and antidyslipidemic agents | GPR119, LIPC, SLC5A2 | PABPC1 4790/4885BCHE 744/4885ACHE 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.